EP0971742A4 - Fettsuchtprotein formulierungen - Google Patents
Fettsuchtprotein formulierungenInfo
- Publication number
- EP0971742A4 EP0971742A4 EP98902618A EP98902618A EP0971742A4 EP 0971742 A4 EP0971742 A4 EP 0971742A4 EP 98902618 A EP98902618 A EP 98902618A EP 98902618 A EP98902618 A EP 98902618A EP 0971742 A4 EP0971742 A4 EP 0971742A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- protein formulations
- obesity protein
- obesity
- formulations
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000008589 Obesity Diseases 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Child & Adolescent Psychology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3571497P | 1997-01-17 | 1997-01-17 | |
| US35714P | 1997-01-17 | ||
| US5488697P | 1997-08-07 | 1997-08-07 | |
| US54886P | 1997-08-07 | ||
| PCT/US1998/000939 WO1998031391A1 (en) | 1997-01-17 | 1998-01-16 | Obesity protein formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0971742A1 EP0971742A1 (de) | 2000-01-19 |
| EP0971742A4 true EP0971742A4 (de) | 2002-04-10 |
Family
ID=26712418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP98902618A Withdrawn EP0971742A4 (de) | 1997-01-17 | 1998-01-16 | Fettsuchtprotein formulierungen |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0971742A4 (de) |
| JP (1) | JP2001509177A (de) |
| AU (1) | AU723997B2 (de) |
| CA (1) | CA2276427A1 (de) |
| WO (1) | WO1998031391A1 (de) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996031526A1 (en) * | 1995-04-06 | 1996-10-10 | Amylin Pharmaceuticals, Inc. | Anti-obesity agents |
| EP0827750A2 (de) * | 1996-08-23 | 1998-03-11 | Eli Lilly And Company | Formulierungen des Obesitäts-Proteins |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5569603A (en) * | 1994-03-08 | 1996-10-29 | Heska Corporation | Dirofilaria immitis GP29 proteins, nucleic acid molecules and uses thereof |
| US5552523A (en) * | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| EP0786256A3 (de) * | 1996-01-19 | 1999-08-18 | Eli Lilly And Company | Formulierungen des Obesitätsproteins |
| JP2000509018A (ja) * | 1996-03-26 | 2000-07-18 | イーライ・リリー・アンド・カンパニー | 肥満タンパク質製剤 |
-
1998
- 1998-01-16 JP JP53459298A patent/JP2001509177A/ja active Pending
- 1998-01-16 CA CA002276427A patent/CA2276427A1/en not_active Abandoned
- 1998-01-16 AU AU59231/98A patent/AU723997B2/en not_active Ceased
- 1998-01-16 EP EP98902618A patent/EP0971742A4/de not_active Withdrawn
- 1998-01-16 WO PCT/US1998/000939 patent/WO1998031391A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996031526A1 (en) * | 1995-04-06 | 1996-10-10 | Amylin Pharmaceuticals, Inc. | Anti-obesity agents |
| EP0827750A2 (de) * | 1996-08-23 | 1998-03-11 | Eli Lilly And Company | Formulierungen des Obesitäts-Proteins |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO9831391A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU723997B2 (en) | 2000-09-07 |
| EP0971742A1 (de) | 2000-01-19 |
| JP2001509177A (ja) | 2001-07-10 |
| AU5923198A (en) | 1998-08-07 |
| CA2276427A1 (en) | 1998-07-23 |
| WO1998031391A1 (en) | 1998-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EG23685A (en) | Activated protein c formulations | |
| EP1113799A4 (de) | Proteinformulierung | |
| GB9703681D0 (en) | Protein complemention | |
| GB9719879D0 (en) | Protein | |
| AU1750997A (en) | Obesity protein formulations | |
| EP1151006A4 (de) | Menschlicher an ein g-protein gekoppelter rezeptor | |
| AU1705197A (en) | Obesity protein formulations | |
| GB9715064D0 (en) | Protein expression | |
| IL139873A0 (en) | Angoistatin-binding protein | |
| GB9700154D0 (en) | Peptides | |
| AU2243997A (en) | Obesity protein formulations | |
| ZA984322B (en) | Sucrose-binding proteins | |
| AU1747297A (en) | Obesity protein formulations | |
| GB9720784D0 (en) | Protein | |
| GB9828880D0 (en) | Protein | |
| AU6569998A (en) | Obesity protein formulations | |
| GB9827016D0 (en) | Receptor protein | |
| EP0983091A4 (de) | Formulierungen auf der basis des proteins für fettleibigkeit | |
| AU4160597A (en) | Protein formulations | |
| GB9602408D0 (en) | Obesity protein formulations | |
| GB9602410D0 (en) | Obesity protein formulations | |
| GB9602409D0 (en) | Obesity protein formulations | |
| GB9602406D0 (en) | Obesity protein formulations | |
| GB9809566D0 (en) | Protein | |
| GB9812607D0 (en) | Protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19990715 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20020227 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE |
|
| RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 38/22 A, 7C 07K 14/575 B |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20020515 |